Analyst Ratings for Nektar Therapeutics (NKTR)
NKTR Rating Summary
NKTR Price Target Summary
- Highest: $192.00 (Piper Sandler)
- Lowest: $53.00 (UBS)
- Average: $136.83
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$136.83 (+282.4%)
* Over Last 12-Mos
Rating Score: 6.2 / 10
Percentile Rank: 65%
Avg. $ Target:
$136.83 (+282.4%)
* Over Last 12-Mos
Rating Score: 6.2 / 10
Percentile Rank: 65%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/12/2026 | Leerink | Will Soghikian | New Coverage | Outperform (N/A) |
130.00 (N/A) |
41.17 (35.78) |
-13.09% | Details |
| 10/12/2026 | UBS | Alice Nettleton | New Coverage | Neutral (N/A) |
53.00 (N/A) |
40.80 (35.78) |
-12.3% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
